# Vusolimogene oderparepvec

Source: https://onco.cc/drugs/vusolimogene-oderparepvec/  
OnCo record `vusolimogene-oderparepvec` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vusolimogene oderparepvec is an engineered herpes virus injected into melanoma tumours, approved in August 2026 with nivolumab after immunotherapy failure.

## Summary

Vusolimogene oderparepvec (RP1) is an engineered herpes simplex virus type 1 that replicates selectively in tumour cells, expresses GM-CSF to recruit antigen-presenting cells and carries the GALV-GP R- fusogenic protein. It is injected into melanoma lesions at 1 x 10^6 PFU/mL for the first dose, then 1 x 10^7 PFU/mL every 2 weeks for up to 8 cycles, with nivolumab. In IGNYTE the combination produced a response rate of about 33% in melanoma that had failed anti-PD-1 therapy, including shrinkage of uninjected lesions, evidence of a systemic immune effect. The FDA issued a complete response letter in July 2025 and then granted accelerated approval on 6 August 2026; the randomised IGNYTE-3 trial must confirm the benefit. Replimune developed it. For a newcomer: a tumour-injected virus that helps immunotherapy work again in melanoma.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-04
- Brand: Tudriqev
- Code: RP1
- Modality: Oncolytic virus (HSV-1)
- Mechanism: Selective replication in tumour cells, cell fusion and lysis, GM-CSF-driven antigen presentation.
- Approvals: US 2026: Unresectable/metastatic melanoma after anti-PD-1, with nivolumab (accelerated)
- Dosing: Intratumoural injection; 1 × 10⁶ PFU/mL first dose, then 1 × 10⁷ PFU/mL every 2 weeks for up to 8 cycles (injectable lesions up to 10 mL), with nivolumab

## Sources

- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vusolimogene%20oderparepvec

## Connected records

- cancers: [Advanced cutaneous squamous cell carcinoma](https://onco.cc/cancers/advanced-cutaneous-scc/), [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/), [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Replimune](https://onco.cc/companies/replimune/)
- trials: [Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma](https://onco.cc/trials/nct06898970/), [VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]](https://onco.cc/trials/nct06264180/)
- pairings: [Oncolytic virus + PD-1 blockade](https://onco.cc/pairings/oncolytic-plus-pd1/)
- roadmaps: [Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity](https://onco.cc/roadmaps/immunotherapy-roadmap/)
- people: [Kevin Harrington](https://onco.cc/people/kevin-harrington/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/)
- ideas: [Oncolytic viruses that make interleukin-12 only inside the tumour](https://onco.cc/ideas/idea-bio2-oncolytic-regulated-il12/)
- key papers: [IGNYTE: an engineered herpes virus with nivolumab in melanoma that had already failed anti-PD-1 therapy](https://onco.cc/key-papers/paper-wong-ignyte-rp1-nivolumab-jco-2025/)
- pathways: [Cold tumours: immune deserts and exclusion](https://onco.cc/pathways/immune-desert-exclusion/)

---
JSON: https://onco.cc/api/v1/entities/vusolimogene-oderparepvec.json